| Entries |
| Document | Title | Date |
|---|
| 20080306247 | ANTIBODY-CONTAINING SOLUTION FORMULATIONS - An antibody-containing solution formulation comprising an organic acid and a surfactant as stabilizers; a method for suppressing the formation of visible insoluble matter and/or insoluble particles due to the presence of metal ions in an antibody-containing solution formulation, which comprises adding an organic acid to the solution; a method for suppressing the formation of visible insoluble matter and/or insoluble particles during shaking and freezing-thawing of an antibody-containing solution, which comprises adding a surfactant to the solution; and a method for stabilizing an antibody-containing solution, which comprises adding an organic acid and a surfactant. | 12-11-2008 |
| 20090012271 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 01-08-2009 |
| 20090018316 | Interleukin-15 receptors - There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures. | 01-15-2009 |
| 20090076251 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention. | 03-19-2009 |
| 20090124791 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 05-14-2009 |
| 20090259028 | PREVENTION OF LEACHING OF LIGANDS FROM AFFINITY-BASED PURIFICATION SYSTEMS - In an affinity-type purification, ligands dissociated from the stationary phase that would otherwise leach into the species being purified are captured by a second ligand that is also incorporated into the stationary phase, the second ligand exhibiting an affinity-type interaction with the dissociated first ligand with sufficient specificity to avoid the undesired retention by the second ligand of species from the liquid sample or source liquid other than the species sought to be purified in the affinity column. | 10-15-2009 |
| 20100063260 | Whitefly Ecdysone Receptor Antibody - The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity. | 03-11-2010 |
| 20100087631 | ANTI-MYOSTATIN ANTIBODIES - A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may he chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species. | 04-08-2010 |
| 20100099854 | NEUROVIRULENT STRAIN OF THE WEST NILE VIRUS AND USES THEREOF - Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof. | 04-22-2010 |
| 20100145031 | METHODS FOR PRODUCING ANTIBODIES FROM PLASMA CELLS - The invention relates to methods of producing antibodies, including monoclonal antibodies, comprising culturing a limited number of plasma cells. It also relates to methods of identifying antibodies by performing assays on the antibodies produced by the cultured plasma cells to determine their function, binding specificity, epitope specificity, and/or their ability to neutralize a toxin or a pathogen. The invention also relates to antibodies and antibody fragments produced by the methods of the invention as well as methods of using the antibodies and antibody fragments. | 06-10-2010 |
| 20100174051 | Asymmertric porous adsorptive bead - The present invention relates to an asymmetric chromatography media suitable for separations applications, particularly as packed bed, fluidized bed or magnetized bed chromatography media. In certain embodiments, the asymmetric chromatography media comprises asymmetric particles, preferably beads, having at least two distinct, controlled pore size distributions. Preferably one of the distinct pore size distributions is in an internal region of the particle, and the other is in an external region or coating on the particle. These distinct pore size distributions can be modified with uniform or alternatively unique functional groups or mixtures of functional groups. The present invention allows for the control over pore size distribution within an asymmetric porous particle by providing a distinct internal region, preferably in the form of a bead, and a distinct external region, preferably in the form of a coating on the bead. | 07-08-2010 |
| 20100174052 | SEPARATION METHOD USING POLYMER MULTI PHASE SYSTEMS - The present invention relates to a process of isolating one or more target compounds, wherein the clarification of feed is performed using partitioning in a multiphase system comprising a first polymer, which is a synthetic poly(acid), a second synthetic polymer, which is a poly(ether), and at least one salt, which clarification is followed by at least one step of affinity chromatography. The molecular weight of the poly(acid) may be in the range of 1000-100,000 Da. The target compound is preferably a biomolecule, such as a monoclonal antibody. | 07-08-2010 |
| 20100190965 | METHOD FOR SEPARATION OF IMMUNOGLOBULIN MONOMERS - A method of accurately separating immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates to cross-flow filtration using an ultrafiltration membrane, an ultrafiltration membrane module, and a cross-flow filtration apparatus. The method can separate immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates and having an immunoglobulin concentration of 1 to 150 g/L to cross-flow filtration using an ultrafiltration membrane having a molecular weight cut-off of 100,000 or more and less than 500,000 so that immunoglobulin monomers passes through the ultrafiltration membrane with a permeability of 80% or more while achieving a fractionation performance in which the permeability ratio of immunoglobulin dimers to immunoglobulin monomers that pass through the ultrafiltration membrane is 0.20 or less. | 07-29-2010 |
| 20100204455 | Antibody Purification Process By Precipitation - The present invention relates to a method of purification of antibodies. An object of the present invention is to provide a method for the isolation of antibodies from a solution containing one or more antibodies, comprising the steps of precipitating the antibody and washing the solid precipitate with washing buffer. Preferably, the antibody is precipitated by using a PEG solution or sodium phosphate. | 08-12-2010 |
| 20100234577 | METHODS FOR PURIFYING ANTIBODIES USING CERAMIC HYDROXYAPATITE - This invention relates to the purification of monoclonal antibodies from mammalian cell culture fluid utilizing sequential, orthogonal chromatography and filtration techniques resulting in material of high purity and quality that is suitable for human administration. The method involves capturing an IgG product using immobilized protein A affinity chromatography, followed by at least one ion exchange technique prior to adsorbing the IgG to hydroxyapatite and selectively eluting the product in a single isocratic step to achieve purification from impurities and simultaneously reducing multiple types of impurities including but not limited to IgG aggregates, residual protein A, non-IgG proteins, host cell proteins, viral particles, and DNA | 09-16-2010 |
| 20100249383 | Novel Ligand Involved In The Transmigration Of Leukocytes Across the Endothelium and Uses Therefor - The present invention provides methods and compositions involved in the inflammatory response, as well as various pathological processes. In particular, the present invention provides novel antibodies directed against novel glycans that are enriched on endothelial cell surfaces. In addition, the present invention provides methods and compositions involved in a previously unrecognized pathway of the inflammatory response and various pathological processes. In addition the present invention provides methods and compositions suitable to mediate the inflammatory response in various settings, as well as methods and compositions for the identification of other inflammatory response mediators. | 09-30-2010 |
| 20100298547 | METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE AS ANTIBODY LIGANDS - The instant invention comprises a process for selecting and manufacturing antibodies useful for therapeutic, prophylactic, diagnostic or research purposes using epitope peptide mixtures synthesized by the solid phase synthesis, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting antibodies are related to but distinct from antibodies that bind to the known epitope. | 11-25-2010 |
| 20100298548 | METHOD FOR PRODUCTION OF SEPARATION MEDIA - The present invention relates to a method for production of separation media using a so called Spinning Disc technology wherein the porosities of the beads are optimized in such a way that a desired biomolecule may be separated from a complex sample. The method comprises the following steps: a) feeding a 4-8% polysaccharide solution, which has a viscosity within 350-450 mPas, at 65-75° C. to one or more spinning discs at 3001-3010 rpm to form polysaccharide beads; b) capturing said formed polysaccharide beads in a capturing bath; wherein the porosity of the polysaccharide beads is controlled by varying the temperature of the capturing between 15 and 27° C., preferably between 17.5 and 24.6° C. The method yields porosities that prevent molecules larger than 150 000 g/mol to diffuse into the beads. The invention also relates to separation media produced by the method and use thereof for purification of biomolecules, in particular monoclonal antibodies. | 11-25-2010 |
| 20110065901 | Methods For Purifying A Target Protein From One or More Impurities In A Sample - The present invention relates, at least in part, to improved methods of protein purification. In particular, the present invention relates, at least in part, to methods for purifying an Fc region containing protein from a composition comprising the Fc region containing protein and one or more impurities, where the methods eliminate the need for a holding tank and/or a buffer exchange step. | 03-17-2011 |
| 20110118445 | Inhibitor protein of the wnt signal pathway - The present invention relates to an inhibitor protein of the wnt signal path, a DNA encoding such a protein and a process for the preparation of such a protein. In addition, this invention concerns the use of the DNA and the protein as well as antibodies directed against the protein. | 05-19-2011 |
| 20110144311 | METHODS FOR PURIFYING ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY - This invention provides a method for purifying a monomeric monoclonal antibody which comprises contacting the sample, wherein the sample comprises the monomeric monoclonal antibody, host cell impurities, dimers, and higher order aggregates, with a Protein A affinity chromatography column; eluting the monomeric monoclonal antibody from the Protein A affinity chromatography column with an elution buffer; and collecting one or more fractions of the monomeric monoclonal antibody to form a Protein A product pool, wherein the product pool comprises less than 5% higher order aggregate, and has a pH from about 3.2 to about 4.5, thereby purifying the monomeric monoclonal antibody from the sample. This invention also provides a method for purifying a monomeric monoclonal antibody which comprises eluting with acetate or citrate, optionally in the presence of amino acids. This invention also provides a method for purifying a monomeric monoclonal antibody which comprises conducting the method within certain temperature ranges. | 06-16-2011 |
| 20110245472 | METHOD FOR THE MASS PRODUCTION OF IMMUNOGLOBULIN CONSTANT REGION - Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an | 10-06-2011 |
| 20110288277 | Media For Membrane Ion Exchange Chromatography Based On Polymeric Primary Amines, Sorption Device Containing That Media, And Chromatography Scheme And Purification Method Using The Same - Media and devices, such as anion exchangers including such media, wherein the media is a membrane having a surface coated with a polymer such as a polyallylamine. The resulting membrane offers stronger binding of protein impurities and superior removal of host cell proteins from biological samples than conventional ligands based on quaternary ammonium salts, including trimethylammonium ligands. Also described is a chromatography scheme and method for purifying monoclonal antibodies, wherein the anion exchange sorber is placed downstream of an affinity column (such as Protein A or Protein G affinity column) and optionally one or more polishing devices such as cationic exchange columns. Little or no dilution of the cation exchanger pool (or affinity column exchange pool where no cation exchanger is used) is necessary to lower the conductivity of the sample. The sorber functions well to strongly bind host cell proteins and other impurities in biological samples even at high conductivities and pH. | 11-24-2011 |
| 20120010390 | SEPARATION METHOD USING SINGLE POLYMER PHASE SYSTEMS - The present invention relates to a process of enriching one target compound from a liquid, which process comprises at least one step of isolation performed by differentially partitioning between two aqueous phases. In the present invention the phases are formed by adding a thermally responsive, self-associating (i.e. clouding) hydrophilic polymer, and if needed some additional salts, to an aqueous biotechnical solution (such as a fermentation sample or bioseparation process stream) under thermal and other conditions where the solution separates into a one polymer, two-phase system with one phase enriched in the polymer. The target compound is to be found in the phase not enriched in the polymer, while a significant though varying percentage of contaminants may differentially partition to the phase interface or the polymer enriched phase. With minor or no modification the target containing phase solution can be further processed via standard unit operations such as precipitation, chromatography, and filtration to further purify target and remove any residual polymer. | 01-12-2012 |
| 20120022239 | PRECIPITATION OF BIOMOLECULES WITH NEGATIVELY CHARGED POLYMERS - The present invention relates to methods of isolating biomolecules. More particularly, the invention relates to methods for isolating antibodies (mAbs) and related proteins including antibody fragments (Fabs) under conditions where they are positive and relatively hydrophobic and will react with negatively charged polymer to form polymer-protein complexes which precipitate. The isolation can be accomplished using inexpensive and biocompatible negatively charged polymers such as polyacrylic acid or carboxymethyldextran polymers of various molecular weights as precipitant. It occurs at relatively high concentrations of polymer (e.g. 10%) and high salt concentration (>50 mM) and conductivity (e.g. > | 01-26-2012 |
| 20120077963 | METHOD FOR REMOVING VIRUSES FROM HIGH CONCENTRATION MONOCLONAL ANTIBODY SOLUTION - An object of the present invention is to provide a method for removing even small viruses from a high concentration monoclonal antibody solution using a membrane, and thus for recovering the antibody within a short time at high yield in the form of a filtrate. The present invention provides a method for producing a preparation containing a monoclonal antibody, which comprises a step of removing viruses by filtering viruses in a monoclonal antibody solution using a virus-removing membrane, wherein
| 03-29-2012 |
| 20120149883 | Detection and quantification of modified proteins - The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes. | 06-14-2012 |
| 20120202975 | ELUTION OF PROTEINS FROM HYDROXYAPATITE RESINS WITHOUT RESIN DETERIORATION - Proteins, including monoclonal antibodies, that have been retained on hydroxyapatite resins for purposes of protein separation, purification, or both, are eluted from the resins by a elution buffer that contains controlled amounts of calcium and phosphate ions. The buffer allows elution to be performed in repeated runs at an acidic pH without deterioration of the resin. | 08-09-2012 |
| 20120202976 | SEPARATION MATRICES - The present invention relates to separation matrices comprising base matrices with first ligands comprising hydrophobic functions covalently bound to said base matrices and with extenders covalently bound to said base matrices, said extenders comprising second ion exchange ligands. | 08-09-2012 |
| 20120264920 | PROCESSES FOR PURIFICATION OF PROTEINS - The invention is directed to a method for purifying a protein. The method involves providing a sample containing the protein, processing the sample through a capture chromatography resin, inactivating viruses in the sample, and processing through at least one depth filter and ion-exchange membrane. | 10-18-2012 |
| 20130012689 | Depth Filters For Disposable Biotechnological Processes - A process for the primary clarification of feeds, including chemically treated flocculated feeds, containing the target biomolecules of interest such as mAbs, mammalian cell cultures, or bacterial cell cultures, using a primary clarification depth filtration device without the use of a primary clarification centrifugation step or a primary clarification tangential flow microfiltration step. The primary clarification depth filtration device contains a porous depth filter having graded porous layers of varying pore ratings. The primary clarification depth filtration device filters fluid feeds, including chemically treated flocculated feeds containing flocculated cellular debris and colloidal particulates having a particle size distribution of approximately about 0.5 μm to 200 μm, at a flow rate of about 10 litres/m | 01-10-2013 |
| 20130023653 | Tissue Specific Expression Of Antibodies In Chickens - Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems. | 01-24-2013 |
| 20130041139 | ENHANCED PROTEIN PURIFICATION THROUGH A MODIFIED PROTEIN A ELUTION - The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH. | 02-14-2013 |
| 20130046080 | METHOD TO IMPROE THE SORBENT EFFICIENCY OF PROTEIN A CHROMATOGRAPHY USING SWITCHING COLUMN WITH CONTINUOUS FEEDING - The present invention relates to a method to improve the sorbent efficiency of protein A chromatography using switching column with continuous feeding. In the chromatography method of the present invention, the increased usage efficiency of the absorbent (resin), the decreased processing time, the decreased operation cycle of column compared to that of single batch-type column, and the reduced amount of used resin are achieved and thus, the target protein can be purified at a high efficiency and a low cost. | 02-21-2013 |
| 20130197200 | METHODS OF REDUCING LEVEL OF ONE OF MORE IMPURITIES IN A SAMPLE DURING PROTEIN PURIFICATION - The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product. | 08-01-2013 |
| 20130203969 | USE OF SMALL MOLECULES IN METHODS FOR PURIFICATION OF BIOMOLECULES - The present invention relates to novel and improved methods for the purification of biomolecules. In particular, the present invention relates to methods of protein purification which employ small molecules, which include at least one non-polar group and at least one cationic group or which include at least one non-polar group and at least one anionic group. | 08-08-2013 |
| 20140046038 | METHOD OF PURIFYING PROTEIN - The present invention relates to a method for purifying a protein by separating the protein from impurities in a non-adsorption mode using an activated carbon. In particular, the present invention relates to a method for purifying an antibody using the activated carbon instead of protein A affinity chromatography. | 02-13-2014 |
| 20140073769 | ASYMMETRIC POROUS ADSORPTIVE BEAD - The present invention relates to an asymmetric chromatography media suitable for separations applications, particularly as packed bed, fluidized bed or magnetized bed chromatography media. In certain embodiments, the asymmetric chromatography media comprises asymmetric particles, preferably beads, having at least two distinct, controlled pore size distributions. Preferably one of the distinct pore size distributions is in an internal region of the particle, and the other is in an external region or coating on the particle. These distinct pore size distributions can be modified with uniform or alternatively unique functional groups or mixtures of functional groups. The present invention allows for the control over pore size distribution within an asymmetric porous particle by providing a distinct internal region, preferably in the form of a bead, and a distinct external region, preferably in the form of a coating on the bead. | 03-13-2014 |
| 20140243508 | METHOD FOR THE PURIFICATION OF ANTIBODIES - A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described. | 08-28-2014 |
| 20140329996 | TISSUE SPECIFIC EXPRESSION OF ANTIBODIES IN CHICKENS - Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of transgene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems. | 11-06-2014 |
| 20140329997 | ACOUSTIC BIOREACTOR PROCESSES - A series of multi-dimensional acoustic standing waves is set up inside a growth volume of a bioreactor. The acoustic standing waves are used to hold a cell culture in place as a nutrient fluid stream flows through the cell culture. Biomolecules produced by the cell culture are collected by the nutrient fluid stream and separated downstream of the cell culture. | 11-06-2014 |
| 20150133642 | CRYSTALLIZATION METHODS FOR PURIFICATION OF MONOCLONAL ANTIBODIES - This application teaches methods for crystallizing antibodies from cell-free culture supernatants. They produce high purity, stable, crystallized monoclonal antibodies suitable for formulation in pharmaceutical products in high yield from cell-free culture supernatant without the use of costly steps or equipment. | 05-14-2015 |
| 20150133643 | Low Organic Extractable Depth Filter Media Processed with Solvent Extraction Method - Provided is a primary clarification depth filtration process of cell-culture feeds, including chemically treated flocculated feeds, containing target biomolecules of interest such as mAbs, mammalian cell cultures, or bacterial cell cultures, utilizing a primary clarification depth filtration device containing a media with significantly lower flushing requirements, resulting in lower levels of organic extractables released after media flushing, and increased throughput for the pre-treated feed streams, without the use of a primary clarification centrifugation step or primary clarification tangential flow microfiltration step. The primary clarification depth filtration device used in the primary clarification of fluid cell culture feeds, including chemically treated flocculated feeds containing flocculated cellular debris and/or colloidal particulates having a particle size distribution of about 0.5 μm to 200 um, contains a porous depth filter media having porous layers of varying pore ratings, and achieves the desired level, of total organic extractables (1-3 ppm) measured in the feed filtered through the media with, significantly lower flushing requirements. Kits and methods of using and making the same are also provided. | 05-14-2015 |
| 20150329589 | COPOLYMERS FOR PROTEIN PRECIPITATION - The present invention relates to the isolation of recombinant and/or biotherapeutic proteins for capture or clarification from cell culture fluid using copolymers. The copolymers used according to the process of the present invention comprise hydrophobic and anionic residues. | 11-19-2015 |
| 20150361128 | METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL LEVELS OF HIGH MANNOSE GLYCOFORMS - Provided are methods of using ion exchange based chromatography to control the levels of high mannose glycoforms in a glycoprotein sample, such as an antibody sample. The high mannose glycoforms can be removed from the sample or isolated and enriched. Also provided is a composition comprising a glycoprotein, such as an antibody, from which the high mannose glycoforms have been reduced or removed or isolated or enriched using an ion exchange based chromatography step. | 12-17-2015 |
| 20150361129 | METHODS FOR INCREASING THE CAPACITY OF FLOW-THROUGH PROCESSES - In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device. | 12-17-2015 |
| 20150376230 | METHODS FOR REDUCING AGGREGATE LEVELS IN PROTEIN PREPARATIONS BY TREATMENT WITH THIO-HETEROCYCLIC CATIONS - A method of reducing the aggregate content in a protein preparation having a target protein includes contacting the protein preparation with a thio-heterocyclic cation to form a mixture, contacting the mixture with at least one functionalized solid to remove excess thio-heterocyclic cations; and optionally contacting the mixture, simultaneously or sequentially, with at least one further functionalized solid to further reduce aggregate content of the protein preparation. | 12-31-2015 |
| 20150376232 | SELECTIVE REMOVAL OF A PROTEIN FROM A MIXTURE OF PROTEINS USING ACTIVATED CARBON BY ADJUSTING SOLUTION CONDITIONS - The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product. | 12-31-2015 |
| 20160016992 | Methods of Reducing Level of One or More Impurities in a Sample During Protein Purification - The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product. | 01-21-2016 |
| 20160083419 | METHOD FOR PURIFYING ANTIBODY PROTEIN - A method for purifying a biologically active substance from a solution mixture containing impurities and the biologically active substance, in which an ion exchange chromatography carrier comprising a matrix and a copolymer containing at least N-isopropylacrylamide as a monomer unit and immobilized to a surface of the matrix is used, and the solution mixture is allowed to flow through a container storing the carrier at a uniform temperature, thereby recovering the biologically active substance. | 03-24-2016 |
| 20160090399 | REMOVAL OF FRAGMENTS FROM A SAMPLE CONTAINING A TARGET PROTEIN USING ACTIVATED CARBON - The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal, of protein, fragments without adversely affecting the yield of the desired protein product. | 03-31-2016 |
| 20160251429 | NEUTRALISING ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17 | 09-01-2016 |
| 20190144543 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | 05-16-2019 |
